These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Cost-effectiveness of lumbar spine radiography in primary care patients with low back pain. Miller P; Kendrick D; Bentley E; Fielding K Spine (Phila Pa 1976); 2002 Oct; 27(20):2291-7. PubMed ID: 12394910 [TBL] [Abstract][Full Text] [Related]
23. One year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial. Weintraub WS; Mahoney EM; Zhang Z; Chu H; Hutton J; Buxton M; Booth J; Nugara F; Stables RH; Dooley P; Collinson J; Stuteville M; Delahunty N; Wright A; Flather MD; De Cock E Heart; 2004 Jul; 90(7):782-8. PubMed ID: 15201249 [TBL] [Abstract][Full Text] [Related]
24. The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes. Orme ME; Jurewicz WA; Kumar N; McKechnie TL Pharmacoeconomics; 2003; 21(17):1263-76. PubMed ID: 14986738 [TBL] [Abstract][Full Text] [Related]
25. United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: cost effectiveness of physical treatments for back pain in primary care. UK BEAM Trial Team BMJ; 2004 Dec; 329(7479):1381. PubMed ID: 15556954 [TBL] [Abstract][Full Text] [Related]
26. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study. Whitfield MD; Gillett M; Holmes M; Ogden E Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425 [TBL] [Abstract][Full Text] [Related]
27. Direct healthcare costs and predictors of costs in patients with primary Sjogren's syndrome. Callaghan R; Prabu A; Allan RB; Clarke AE; Sutcliffe N; Pierre YS; Gordon C; Bowman SJ; Rheumatology (Oxford); 2007 Jan; 46(1):105-11. PubMed ID: 16728437 [TBL] [Abstract][Full Text] [Related]
28. Economic evaluation of nurse led intermediate care versus standard care for post-acute medical patients: cost minimisation analysis of data from a randomised controlled trial. Walsh B; Steiner A; Pickering RM; Ward-Basu J BMJ; 2005 Mar; 330(7493):699. PubMed ID: 15757959 [TBL] [Abstract][Full Text] [Related]
29. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Wade AG; Toumi I; Hemels ME Curr Med Res Opin; 2005 Apr; 21(4):631-42. PubMed ID: 15899113 [TBL] [Abstract][Full Text] [Related]
30. An economic analysis of specialist heart failure nurse management in the UK; can we afford not to implement it? Stewart S; Blue L; Walker A; Morrison C; McMurray JJ Eur Heart J; 2002 Sep; 23(17):1369-78. PubMed ID: 12191748 [TBL] [Abstract][Full Text] [Related]
31. Assessing the total costs of blood delivery to hospital oncology and haematology patients. Agrawal S; Davidson N; Walker M; Gibson S; Lim C; Morgan CL; Cowell W Curr Med Res Opin; 2006 Oct; 22(10):1903-9. PubMed ID: 17022848 [TBL] [Abstract][Full Text] [Related]
32. The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS. Palmer SJ; Brady AJ; Ratcliffe AE Int J Clin Pract; 2003 Nov; 57(9):792-800. PubMed ID: 14686571 [TBL] [Abstract][Full Text] [Related]
33. Costs and cost effectiveness of cardiovascular screening and intervention: the British family heart study. Wonderling D; McDermott C; Buxton M; Kinmonth AL; Pyke S; Thompson S; Wood D BMJ; 1996 May; 312(7041):1269-73. PubMed ID: 8634617 [TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Mihaylova B; Briggs A; Armitage J; Parish S; Gray A; Collins R; Lancet; 2005 May 21-27; 365(9473):1779-85. PubMed ID: 15910950 [TBL] [Abstract][Full Text] [Related]
35. Cost-utility analysis of physiotherapy treatment compared with physiotherapy advice in low back pain. Rivero-Arias O; Gray A; Frost H; Lamb SE; Stewart-Brown S Spine (Phila Pa 1976); 2006 May; 31(12):1381-7. PubMed ID: 16721304 [TBL] [Abstract][Full Text] [Related]
36. Cost and health status analysis after autologous chondrocyte implantation and mosaicplasty: a retrospective comparison. Derrett S; Stokes EA; James M; Bartlett W; Bentley G Int J Technol Assess Health Care; 2005; 21(3):359-67. PubMed ID: 16110716 [TBL] [Abstract][Full Text] [Related]
37. A decision analytical cost analysis of offering ECV in a UK district general hospital. James M; Hunt K; Burr R; Johanson R BMC Health Serv Res; 2001; 1():6. PubMed ID: 11472641 [TBL] [Abstract][Full Text] [Related]
38. Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain. Lopez-Bastida J; Serrano-Aguilar P; Perestelo-Perez L; Oliva-Moreno J Neurology; 2006 Dec; 67(12):2186-91. PubMed ID: 17190942 [TBL] [Abstract][Full Text] [Related]
39. Costs and disability among stroke patients. Kavanagh S; Knapp M; Patel A J Public Health Med; 1999 Dec; 21(4):385-94. PubMed ID: 11469359 [TBL] [Abstract][Full Text] [Related]
40. UK government gives 1.25 billion pounds sterling cash boost to science research. Frankish H Lancet; 2002 Jul; 360(9329):316. PubMed ID: 12147384 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]